Press Releases April 30, 2026 07:30 AM

SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results

SIGA Technologies schedules Q1 2026 financial results and business update call on May 7, 2026

By Ajmal Hussain SIGA
SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results
SIGA

SIGA Technologies, a commercial-stage pharmaceutical company specializing in treatments and prevention of infectious diseases, announced a webcast and conference call on May 7, 2026, to discuss its first-quarter 2026 financial results and provide a business update. CEO Diem Nguyen and CFO Daniel Luckshire will participate in the call, which will be accessible via webcast and phone, with a replay available online and by phone.

Key Points

  • SIGA is hosting a webcast and conference call to discuss Q1 2026 financial results and business updates on May 7, 2026.
  • The company focuses on innovative medicines for infectious diseases, particularly orthopoxviruses, working with governments and public health agencies.
  • SIGA is committed to providing essential countermeasures against severe infectious diseases occurring naturally or intentionally, impacting the global health and pharmaceutical sectors.

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 7, 2026. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time.

Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers.

A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1158847. The archived webcast will be available in the Investor Relations section of the Company's website.

About SIGA
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. For more information about SIGA, visit www.siga.com.

Contact:
Suzanne Harnett
[email protected]


Risks

  • The article does not disclose any specific financial results or forward guidance, creating uncertainty about the company's upcoming performance.
  • Dependence on government and public health agency partnerships may impact revenue and operational stability depending on policy changes or funding availability.
  • As a pharmaceutical company focused on infectious diseases, SIGA faces inherent risks related to regulatory approvals, clinical trial outcomes, and potential competitive pressures, affecting the biotech and healthcare sectors.

More from Press Releases

Figure Technology Solutions Reports April 2026 Operating Data May 4, 2026 Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 4, 2026 TWFG Insurance Acquires APIA Inc., Expanding Specialty MGA Capabilities and Supporting Long-Term Growth May 4, 2026 Pennant Announces First Quarter 2026 Earnings Release and Call May 4, 2026 Magna Announces 2026 Annual Meeting Results May 4, 2026